News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Israeli drone strike near a Gaza school killed at least 10, increasing Middle East geopolitical risk.
  • Trump issued an ultimatum to Iran, threatening overnight strikes and citing retrieval of a U.S. pilot, raising escalation risk.
  • Fed officials Goolsbee and Hammack said inflation is the primary concern and signaled preference for tighter policy as energy costs rise.
  • ConocoPhillips recommended as a measured long, citing strong cash flow and higher oil, while chokepoint risks could limit upside.
  • Okta positioned as a potential identity control plane for agentic AI with a trade target of $110 over 180 trading days.
  • White House proposes cutting TSA headcount by over 9,400 and $1.5 billion, shifting screening at smaller airports to contractors.

Latest Articles

As AI Collides with Legacy Contact Center Technology, TTEC Digital’s Latest Software Release Is Rewriting the Enterprise AI Playbook

As AI Collides with Legacy Contact Center Technology, TTEC Digital’s Latest Software Release Is Rewriting the Enterprise AI Playbook

TTEC Digital has introduced AI Gateway, a software solution that enables enterprises to integrate modern AI capabilities with existing contact center technology without costly system overhauls. The platform supports connections with leading AI providers and CX systems, allowing clients to deploy, test, and scale AI flexibly, resulting in early repo…

Roadzen to Present at Maxim Group’s “Powering the AI Revolution” Virtual Conference on Tuesday April 7, 2026 at 8:30am ET

Roadzen to Present at Maxim Group’s “Powering the AI Revolution” Virtual Conference on Tuesday April 7, 2026 at 8:30am ET

Roadzen Inc., a Nasdaq-listed AI company integrating insurance and mobility solutions, announced it will present at the 'Powering the AI Revolution' virtual conference hosted by Maxim Group. The presentation will highlight Roadzen’s AI-driven technology that enhances safety, reduces claims costs, and improves underwriting across international marke…

Diginex Appoints Chief Operating Officer and Chief Administrative Officer to Accelerate Implementation of Business Strategy

Diginex Appoints Chief Operating Officer and Chief Administrative Officer to Accelerate Implementation of Business Strategy

Diginex Limited appoints Jacob Friedman as Chief Operating Officer and Sandra Kovacheva as Chief Administrative Officer to accelerate the integration of its four operating entities into a unified global platform. These leadership enhancements aim to boost operational efficiency, governance, and compliance as Diginex advances its strategy to deliver…

TransUnion Introduces TruIQ Credit Strategy Studio to Transform How Lenders Build and Launch Prescreen Marketing Campaigns

TransUnion Introduces TruIQ Credit Strategy Studio to Transform How Lenders Build and Launch Prescreen Marketing Campaigns

TransUnion introduced TruIQ Credit Strategy Studio, a self-service platform that drastically reduces prescreen campaign build times for lenders by up to 75%. The tool features no-code, drag-and-drop capabilities, real-time collaboration, and interactive dashboards, streamlining campaign development and enabling faster market responsiveness. Integra…

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

MiNK Therapeutics disclosed that its investigational allogeneic iNKT cell therapy, agenT-797, will be featured at the ASGCT 2026 meeting. The therapy harnesses innate and adaptive immunity to target cancer, immune-mediated diseases, and severe pulmonary inflammation. The presentation underscores agenT-797's potential to modulate adaptive immune res…

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer

Context Therapeutics announced that the FDA has granted Fast Track Designation to its investigational drug CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody, aimed at treating platinum-resistant ovarian cancer. The company is conducting a Phase 1 clinical trial with interim data expected in June 2026. This designation could expedite the de…

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

Plus Therapeutics, through its subsidiary CNSide Diagnostics, secured a reimbursement coverage agreement with Highmark for its CNSide CSF Tumor Cell Enumeration assay, increasing total covered lives from approximately 67 million to 75 million. This expands patient access and supports broader adoption of CNSide in the detection and monitoring of met…

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Bio announced it received a U.S. patent covering the use of its investigational drug buntanetap in preventing and treating neurological injuries caused by brain infections, including those linked to Alzheimer's disease. The patent extends through 2044 and covers both preventive and therapeutic applications against a range of infectious agen…

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics announced inducement stock option grants to two new employees, totaling 52,450 shares at an exercise price of $6.39 per share. The options vest over four years with a ten-year term, granted to attract talent under Nasdaq inducement rules. Cartesian is advancing its lead CAR-T therapy, Descartes-08, in clinical trials for auto…

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene Inc., a clinical-stage biotech company specializing in novel antibody-based cancer immunotherapies, announced the pricing of an underwritten public offering of 18.67 million ADSs at $3.75 each, raising gross proceeds of approximately $70 million. The offering attracted participation from both new and existing institutional investors and is …

Oportun Provides Updates on Leadership Transition

Oportun Provides Updates on Leadership Transition

Oportun Financial Corporation announced that Kate Layton and Gaurav Rana will serve as interim co-CEOs following the departure of CEO Raul Vazquez. Both executives will retain their current roles while leading the company during the CEO search. Vazquez will continue as an advisor until July 2026 to facilitate a smooth transition. The board is activ…

Freight Technologies Announces Strategic Update on Transition to AI-Powered, Software-First Logistics Technology Company

Freight Technologies Announces Strategic Update on Transition to AI-Powered, Software-First Logistics Technology Company

Freight Technologies announced significant progress in transforming into a software-first, AI-native logistics technology company, focusing on scaling its AI-powered platforms like Fleet Rocket, Zayren, and Fr8Radar. The company is exploring strategic alternatives for its traditional brokerage operations to concentrate resources on its AI software …

Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets

Scorpio Tankers Inc. Announces Strategic Collaboration with AMPERA, Inc. to Develop & Commercialize Micronuclear Solutions for Global Marine and Shipping Markets

Scorpio Tankers Inc. has entered into a strategic collaboration with AMPERA, Inc. to jointly develop and commercialize advanced micronuclear power solutions aimed at powering maritime vessels, offshore, and port infrastructure with zero carbon emissions. The collaboration focuses on deploying ultra-safe micro nuclear reactors, including floating nu…

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Announces Founder’s Purchase of Its ADSs

Burning Rock Biotech Limited announced that founder, chairman, and CEO Yusheng Han purchased 31,487 American Depositary Shares (ADSs) for $546,603.90 on the open market, adding to prior purchases this year. These transactions signal strong insider confidence in the company's precision oncology business, which focuses on next generation sequencing (…

Acuity Reports Fiscal 2026 Second-Quarter Results

Acuity Reports Fiscal 2026 Second-Quarter Results

Acuity Inc. delivered a robust second-quarter fiscal 2026 performance marked by 5% net sales growth to $1.1 billion, 21% increase in operating profit to $133 million, and a 26% rise in diluted EPS to $3.09. The company's two business segments had mixed results: Acuity Brands Lighting sales slightly declined by 2.8%, while Acuity Intelligent Spaces …

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Roivant Sciences announced the expansion of its brepocitinib development program to include a new seamless Phase 2b/3 clinical trial for the inflammatory scalp disorder lichen planopilaris (LPP), which currently has no FDA-approved treatments. Concurrently, Roivant reported topline results from Immunovant's Phase 3 studies of batoclimab in thyroid …

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

Priovant Therapeutics announced the initiation of a seamless Phase 2b/3 clinical trial for brepocitinib in treating Lichen Planopilaris (LPP), a severe inflammatory scalp disorder with no FDA-approved treatments. This marks the fourth indication in brepocitinib's late-stage development alongside dermatomyositis, non-infectious uveitis, and cutaneou…

Futu Announces Cash Dividend

Futu Announces Cash Dividend

Futu Holdings Limited, a Nasdaq-listed online brokerage and wealth management platform, declared a cash dividend of $0.325 per ordinary share (equivalent to $2.6 per American Depositary Share), totaling approximately $365 million, payable to shareholders as of April 16, 2026, with payment expected around April 29, 2026.